---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-011430"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2025-01-31T23:59:59+00:00"
generated_at: "2026-05-27T04:41:22.791746+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health prioritizes Revita weight maintenance, Rejuva gene therapy; cuts 17% workforce

## Summary
- REMAIN-1 pivotal study for weight maintenance post-GLP-1 withdrawal; midpoint data analysis expected Q2 2025, full enrollment summer 2025.
- Rejuva gene therapy candidate RJVA-001 completed key preclinical studies; first-in-human studies planned H1 2025.
- Pausing Revita T2D programs (REVITALIZE-1 and German Real-World Registry) to focus resources.
- Workforce reduction of 22 employees (~17%) with estimated severance costs of $1.8M; cash runway extended into 2026.

## SEC filing metadata
- accession: 0000950170-25-011430
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2025-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017025011430/0000950170-25-011430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017025011430/guts-20250131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-011430
- JSON: https://secwatch.observer/filing/0000950170-25-011430.json
- Plain text: https://secwatch.observer/filing/0000950170-25-011430.txt

## Key facts
- Restructurings & Charges
  FRACTYL HEALTH, INC. announced a restructuring with charges of approximately $1.8 million affecting the Company (22 employees, or approximately 17% of the Company’s workforce).
  - Type: restructuring
  - Charge: approximately $1.8 million
  - Affected area: the Company
  - Headcount: 22 employees, or approximately 17% of the Company’s workforce
  source text: implemented by the second quarter of 2025. In connection with the Strategic Reprioritization, the Company estimates that it will incur cash charges of approximately $1.8 million related to severance, employee benefits, and other related personnel reduction costs. At this time, the Company is unable in good faith to make a determination of other estimated
  evidence_url: https://www.sec.gov/Archives/edgar/data/1572616/000095017025011430/0000950170-25-011430-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.